Alpers-Huttenlocher syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:726OMIM:203700G31.8
Who is this for?
Show terms as
2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Alpers-Huttenlocher syndrome (also known as Alpers syndrome, Alpers disease, or progressive neuronal degeneration of childhood with liver disease) is a severe, autosomal recessive mitochondrial DNA depletion disorder most commonly caused by biallelic pathogenic variants in the POLG gene, which encodes the catalytic subunit of mitochondrial DNA polymerase gamma. The disease primarily affects the brain and liver, leading to a characteristic clinical triad of refractory seizures (often epilepsia partialis continua), psychomotor regression, and hepatic dysfunction that can progress to liver failure. Onset typically occurs in infancy or early childhood, though later presentations have been reported. The neurological deterioration is progressive and includes intractable seizures, loss of previously acquired developmental milestones, cortical visual impairment, hypotonia, spasticity, and eventual severe encephalopathy. Liver involvement ranges from elevated transaminases to fulminant hepatic failure, which may be triggered or worsened by exposure to valproic acid — a medication that is strictly contraindicated in this condition. Additional features may include feeding difficulties, failure to thrive, and movement abnormalities such as ataxia or myoclonus. There is currently no cure for Alpers-Huttenlocher syndrome, and treatment remains supportive and symptomatic. Seizure management is particularly challenging, as the epilepsy is often refractory to standard antiepileptic drugs, and valproate must be avoided due to the risk of precipitating fatal hepatotoxicity. Nutritional support, physical therapy, and management of liver complications are important components of care. Liver transplantation has been considered in some cases but remains controversial due to the progressive neurological decline. The prognosis is poor, with most affected individuals surviving months to a few years after symptom onset, though the clinical course can be variable.

Also known as:

Clinical phenotype terms— hover any for plain English:

Progressive spasticityHP:0002191ParaparesisHP:0002385
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Alpers-Huttenlocher syndrome.

View clinical trials →

No actively recruiting trials found for Alpers-Huttenlocher syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Alpers-Huttenlocher syndrome community →

Specialists

2 foundView all specialists →
MM
Michio Hirano, MD
NEW YORK, NY
Specialist
PI on 10 active trials
VM
Vinay Penematsa, MD
Specialist
PI on 4 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Alpers-Huttenlocher syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Alpers-Huttenlocher syndromeForum →

No community posts yet. Be the first to share your experience with Alpers-Huttenlocher syndrome.

Start the conversation →

Latest news about Alpers-Huttenlocher syndrome

No recent news articles for Alpers-Huttenlocher syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Alpers-Huttenlocher syndrome

What is Alpers-Huttenlocher syndrome?

Alpers-Huttenlocher syndrome (also known as Alpers syndrome, Alpers disease, or progressive neuronal degeneration of childhood with liver disease) is a severe, autosomal recessive mitochondrial DNA depletion disorder most commonly caused by biallelic pathogenic variants in the POLG gene, which encodes the catalytic subunit of mitochondrial DNA polymerase gamma. The disease primarily affects the brain and liver, leading to a characteristic clinical triad of refractory seizures (often epilepsia partialis continua), psychomotor regression, and hepatic dysfunction that can progress to liver failur

How is Alpers-Huttenlocher syndrome inherited?

Alpers-Huttenlocher syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Which specialists treat Alpers-Huttenlocher syndrome?

2 specialists and care centers treating Alpers-Huttenlocher syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.